Acrolein inhibits NADH-linked mitochondrial enzyme activity: Implications for Alzheimer's disease

Neurotoxicity Research

Volumn 5, Issue 7, 2003, Pages 515-519

  Pocernich, Chava B ^a   Butterfield, D Allan ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Ketoglutarate dehydrogenase; Acrolein; Lipoic acid; Mitochondria; Pyruvate dehydrogenase

Indexed keywords

ACROLEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXOGLUTARATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE COMPLEX; THIOCTIC ACID;

ALZHEIMER DISEASE; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MITOCHONDRION;

ACROLEIN; ALZHEIMER DISEASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; KETOGLUTARATE DEHYDROGENASE COMPLEX; MITOCHONDRIA; NAD; PYRUVATE DEHYDROGENASE COMPLEX; THIOCTIC ACID;

EID: 1342306400     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033161     Document Type: Article

References (33)

1. Blass JP (2000) The mitochondrial spiral: An adequate cause of dementia in Alzheimer syndrome. Ann. NY Acad. Sci. USA 924, 170-183.
2. Brown JP and RN Perham (1976) Selective inactivation of the transacylase components of the 2-oxo acid dehydrogenase multienzyme complexes of Escherichia coli. Biochem. J. 155, 419-427.
3. Boveris A, N Oshino and B Chance (1972) The cellular production of hydrogen peroxide. Biochem. J. 128, 617-630.
4. Butterfield DA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. 36, 1307-1313.
5. Butterfield DA and C Lauderback (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32, 1050-1060.
6. Butterfield DA and ER Stadtman (1997) Protein oxidation processes in brain aging. Adv. Cell. Aging Gerontol. 2, 161-191.
7. Butterfield DA, J Drake, C Pocernich and A Castegna (2001) Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol. Med. 7, 548-554.
8. Butterfield DA, A Castegna, CM Lauderback and J Drake (2002) Review: evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contributes to neuronal death. Neruobiol. Aging 23, 655-664.
9. Calingasan NY, K Uchida and GE Gibson (1999) Protein-bound acrolein: A novel marker of oxidative stress in Alzheimer's disease. J. Neurochem. 72, 751-756.
10. Castegna A, M Aksenov, M Aksenova, V Thongboonkerd, JB Klein, WM Pierce, R Booze, WR Markesbery and DA Butterfield (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part i: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33, 562-571.
11. Castegna A, V Thongboonkerd, JB Klein, B Lynn, WR Markesbery and DA Butterfield (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85, 1394-1401.
12. Chung FL, R Young and SS Hecht (1984) Formation of cyclic 1, N 2 -propanodeoxyguanosine adducts in DNA upon reaction with acrolein or crotonaldehyde. Cancer Res. 44, 990-995.
13. Gibson GE, KF Sheu, JP Blass, A Baker, KC Carlson, B Harding and P Perrino (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch. Neurol. 45, 836-840.
14. Gibson GE, DFR Sheu and JP Blass (1998) Abnormalities of mitochondrial enzmes in Alzheimer disease. J. Neural. Transm. 105, 855-870.
15. Hensley K, N Hall, R Subramaniam, P Cole, M Harris, M Aksenov, M Aksenova, SP Gabbita, JF Wu, JM Carney, M Lovell, WR Markesbery and DA Butterfield (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146-2156.
16. Horton ND, BM Mamiya and JP Kehrer (1997) Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Toxicology 122, 111-122.
17. Lauderback CM, JM Hackett, FF Huang, JN Keller, LI Szweda, WR Markesbery and DA Butterfield (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain. J. Neurochem. 78, 413-416.
18. Lovell MA, C Xie and WR Markesbery (2001) Acrolein, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease and is toxic to primary hippocampal cultures. Neurobiol. Aging 22, 187-194.
19. Lovell MA, WD Ehmann, SM Butler and WR Markesbery (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601.
20. Lovell MA, C Xie and WR Markesbery (2000) Acrolein a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic. Biol. Med., 29, 714-720.
21. Lyras L, NJ Cairns, A Jenner, P Jenner and B Halliwell (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68, 2061-2069.
22. Markesbery WR and MA Lovell (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 19, 33-36.
23. Marnett LJ (1994) DNA adducts of α,βs-unsaturated aldehydes and dicarbonyl compounds. IARC Sci. Publ. 125, 151-163.
24. Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1, 120-129.
25. Ohno Y and K Ormstad (1985) Formation, toxicity and inactivation of acrolein during biotransformation of cyclophosphamide as studied in freshly isolated cells from rat liver and kidney. Arch. Toxicol. 57, 99-103.
26. Picklo MJ and TJ Montine (2001) Acrolein inhibits respiration in isolated brain mitochondria. Biochim. Biophys. Acta. 1535, 145-152.
27. Pocernich CB, AL Cardin, CL Racine, CM Lauderback and DA Butterfield (2001) Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: Relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem. Int. 39, 141-149.
28. Ruggiero FM, F Cafagna, V Petruzzella, MN Gadaleta and E Quagliariello (1992) Lipid composition in synaptic and nonsynaptic mitochondria from rat brains and effect of aging. J. Neurochem. 59, 487-491.
29. Sayre LM, DA Zelasko, PLR Harris, G Perry, RG Salomon and MA Smith (1997) 4-hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68, 2092-2097.
30. Smith MA, PLR Harris, LM Sayre and G Perry (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94, 9866-9868.
31. Tirmenstein MA, PI Mathias, JE Snawder, HE Wey and M Toraason (1997) Antimony-induced alterations in thiol homeostasis and adenine nucleotide status in cultured cardiac myocytes. Toxicol. 119, 203-211.
32. Turrens J (1997) Superoxide production by the mitochondrial respiratory chain. Biosci. Rep. 17, 3-8.
33. Uchida K, M Kanematsu, K Sakai, T Matsuda, N Hattori, Y Mizuno, D Suzuki, T Miyata, N Noguchi, E Niki and T Osawa (1998) Protein-bound acrolein: Potential markers for oxidative stress. Proc. Natl. Acad. Sci. USA 95, 4882-4887.